

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 80573

Title: Envafolimab combined with carboplatin and etoposide in the treatment of extensive stage combined small cell lung cancer: a case report and literature review

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06406907

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2022-10-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-04 14:47

Reviewer performed review: 2022-11-28 09:09

Review time: 23 Days and 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

Thank you for inviting me to evaluate the article entitled “Envafolimab combined with carboplatin and etoposide in the treatment of extensive-stage combined small cell lung cancer: A case report and literature review”. Herein, I recommend this manuscript should be minor revised. The following are the questions and some mistakes in this manuscript: 1. Eliminate multiple duplicate content. After that please check the manuscript thoroughly and eliminate all or reduce duplicate content. For instance, “Combined small cell lung cancer is a special subtype of small cell lung cancer that is relatively rare, aggressive, and prone to early metastasis and has a poor prognosis”, it repeated too often. 2. Eliminate multiple references. Eliminate the lumps in the manuscript. This should be done by characterizing each reference individually. This can be done by mentioning 1 or 2 phrases per reference to show how it is different from the others and why it deserves mentioning. 3. Refer to the reference format of the journal. Determine the document format according to the author guidelines. The number of authors mentioned in the references should be consistent. 4. Prognosis of this case should be included. In addition to the obvious reduction of pulmonary lesions, other aspects of the case, such as survival period, can also be followed up. 5. Reorganize the full text to strengthen the logic. Check the full text carefully, the logic of the article should be modified to make it more readable.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 80573

Title: Envafolimab combined with carboplatin and etoposide in the treatment of extensive stage combined small cell lung cancer: a case report and literature review

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06418652

Position: Peer Reviewer

Academic degree: PhD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-10-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-12-01 08:45

Reviewer performed review: 2022-12-13 06:25

Review time: 11 Days and 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

1) In Treatment section, the units of chemotherapy should be stated as "mg/m²" and "area under the curve, 5 mg min/mL", instead of "mg". The dosing schedule and duration of one cycle should also be described. 2) When using the words "N-SCLC" and "P-SCLC" for the first time, they should not be abbreviated. 3) The authors detailed previous reports of this rare disease. A table summarizing them would be helpful for better understanding.